Wie hoch ist der Preis für Odyssey Therapeutics, Inc. (ODTX)

Preis für Odyssey Therapeutics, Inc. (ODTX) ist $24.55

Wie hoch ist die Marktkapitalisierung für Odyssey Therapeutics, Inc. (ODTX)

Marktkapitalisierung für Odyssey Therapeutics, Inc. (ODTX) ist $1.18B

Odyssey Therapeutics, Inc. (ODTX) Gewinne

Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on discovering and developing novel treatments for autoimmune and inflammatory diseases. Its diverse pipeline features several key drug candidates: OD-001, an oral small molecule that inhibits receptor-interacting protein kinase 2, which is currently in Phase 2a clinical trials for ulcerative colitis. Also included is OD-002, an oral small molecule SLC15A4 inhibitor engineered to prevent harmful inflammatory responses driven by TLR7/8/9-mediated activation of interferon regulatory factor 5 (IRF5). Another program, OD-003, is a protein therapeutic designed to selectively agonize tumor necrosis factor receptor 2 on T regulatory cells. Further assets in its portfolio comprise a bispecific antagonist targeting TSLP and IL-33, an oral small molecule functioning as an interleukin-1 receptor-associated kinase 4 scaffolding inhibitor, and a separate small molecule inhibitor specifically targeting IRF5. The company was founded in 2021 and is headquartered in Boston, Massachusetts.

Jahr	Gewinn	ändert
Nicht genügend Daten für die angegebenen Daten.

Jahr

Gewinn

ändert

Nicht genügend Daten für die angegebenen Daten.

Unternehmen	Gewinn	Gewinnunterschied	Land
Vertex Pharmaceuticals Incorporated VRTX.US	$5.27B	-	US
Argenx SE ARGX.US	$1.95B	-	NL
CSL Limited CSL.AX	$-4.02B	-	AU
Moderna, Inc. MRNA.US	$-3.09B	-	US
Lonza Group AG LONN.SW	-	-	CH

Unternehmen

Gewinn

Gewinnunterschied

Land